NAAT market seen reaching $22.1 billion by 2030

The global nucleic acid amplification testing market is projected to grow from $11.03 billion in 2025 to $22.1 billion by 2030, driven by infectious disease demand, faster diagnostics and broader molecular testing use. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth through 2030.

Why it matters: - Nucleic acid amplification testing is a core molecular diagnostic tool for detecting DNA or RNA quickly and accurately. - Faster NAAT adoption can improve early infection detection, support treatment decisions and help limit disease spread. - The market outlook signals continued demand for rapid diagnostics across hospitals, laboratories and point-of-care settings.

What happened: - The Business Research Company released a report on the nucleic acid amplification testing market covering 2026 to 2035. - The market is projected to rise from $11.03 billion in 2025 to $12.7 billion in 2026. - The forecast shows the market reaching $22.1 billion by 2030. - The report also highlights a 15.2% CAGR in 2026 and a 14.8% CAGR through 2030.

The details: - NAAT detects and amplifies specific DNA or RNA sequences in a sample. - High sensitivity makes NAAT useful for identifying pathogens in the early stages of infection. - Researchers also use NAAT to study gene expression, genetic variation and disease mechanisms. - Earlier market growth was driven by infectious disease outbreaks, broader PCR adoption, more clinical laboratories, public health screening programs and lower assay costs. - Future growth is expected to come from personalized medicine, demand for quick diagnostic tools, expansion in emerging markets, miniaturized technology and regulatory approvals for new assay methods. - Key trends include rapid point-of-care molecular tests, multiplex and syndromic panels, isothermal amplification techniques, home-based and decentralized testing, and stronger focus on early disease detection. - The report says North America held the largest share of the global market in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also says the 2026 report edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.

Between the lines: - Rising infectious disease rates remain a major demand driver because NAAT can identify pathogens quickly enough to support earlier care decisions. - The shift toward decentralized and home-based testing suggests the market is moving beyond centralized laboratories. - Regional growth patterns imply mature markets will remain large, while emerging markets may contribute more incremental expansion. - Public health surveillance data, including 4,216 influenza-related hospitalizations reported in Canada for the 2022-2023 season, helps explain why demand for molecular diagnostics continues to rise.

What's next: - Market growth is expected to continue as developers push rapid molecular formats and broader panel-based testing. - Adoption will likely increase as regulators approve more novel assay methods and healthcare providers expand decentralized testing. - The report positions Asia-Pacific as the main growth engine through 2030 while North America remains the largest market in the near term.

The bottom line: - NAAT is moving from a specialized diagnostic method to a broader testing platform, and the market outlook points to strong global expansion through 2030.